Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 12:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Open label H.P. Acthar Gel Clear all
Terminated Phase 4 Interventional Results available

ACTHar in the Treatment of Lupus Nephritis

NCT02226341
View directory record Official record
Conditions
Lupus Nephritis
Interventions
CellCept, ACTHar gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
16 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 28, 2026, 12:17 AM EDT
Completed Not applicable Interventional Results available

Ocular Sarcoidosis Open Label Trial of ACTHAR Gel

NCT02725177
View directory record Official record
Conditions
Ocular Sarcoidosis, Panuveitis, Anterior Uveitis
Interventions
Repository Corticotropin Injection, Repository Corticotropin Injection -Treatment Extension
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 28, 2026, 12:17 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

NCT06964269
View directory record Official record
Conditions
Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis
Interventions
Acthar Gel 80 UNT/ML Injectable Solution
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 28, 2026, 12:17 AM EDT
Completed Phase 2 Interventional

A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines

NCT01813591
View directory record Official record
Conditions
Chronic Migraine
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Springfield, Missouri • Reno, Nevada • Amherst, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 28, 2026, 12:17 AM EDT
Completed Phase 3 Interventional Results available

Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

NCT02282930
View directory record Official record
Conditions
Progressive IgA Nephropathy, Proteinuria
Interventions
ACTH (Acthar) Gel
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
4
States / cities
Palo Alto, California • Jacksonville, Florida • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 28, 2026, 12:17 AM EDT
Not listed Phase 2 Interventional

A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis

NCT03465111
View directory record Official record
Conditions
Scleritis
Interventions
ACTH (adrenocorticotropic hormone) gel
Drug
Lead sponsor
Metropolitan Eye Research & Surgery Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Palo Alto, California • Palisades Park, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 28, 2026, 12:17 AM EDT
Not listed Not applicable Interventional

Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses

NCT01900093
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Acthar Gel
Drug
Lead sponsor
Aaron Miller
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 28, 2026, 12:17 AM EDT
Completed Phase 4 Interventional Results available

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

NCT01753401
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Acthar, Placebo, Steroid Drug
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 28, 2026, 12:17 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)

NCT03656692
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions
Acthar Gel
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Clearwater, Florida • Indianapolis, Indiana • Waltham, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 28, 2026, 12:17 AM EDT
Not listed Phase 4 Interventional

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

NCT01939132
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Open label H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Sep 28, 2026, 12:17 AM EDT
Withdrawn Phase 4 Interventional

ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

NCT01926054
View directory record Official record
Conditions
SLE Glomerulonephritis Syndrome, WHO Class V
Interventions
Acthar gel
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 28, 2026, 12:17 AM EDT
Completed Phase 4 Interventional Results available

Impact of Acthar on Everyday Life of Participants With Severe Keratitis

NCT04169061
View directory record Official record
Conditions
Keratitis
Interventions
Acthar
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Glendale, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Sep 28, 2026, 12:17 AM EDT
Terminated Phase 4 Interventional Results available

Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis

NCT02769702
View directory record Official record
Conditions
Uveitis
Interventions
Acthar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 30, 2018 · Synced Sep 28, 2026, 12:17 AM EDT
Completed Phase 4 Interventional

Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

NCT01769937
View directory record Official record
Conditions
Lupus Erythematosus Systemic Exacerbation
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Fiechtner, Justus J., M.D., P.C.
Individual
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Sep 28, 2026, 12:17 AM EDT
Completed Phase 4 Interventional Results available

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

NCT02764697
View directory record Official record
Conditions
Uveitis, Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Scleritis, Clinically Significant Macular Edema
Interventions
H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
Drug
Lead sponsor
Tampa Bay Uveitis Center, LLC
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 28, 2026, 12:17 AM EDT
Completed Not applicable Interventional Results available

ACTH Gel Therapy in Rheumatoid Arthritis

NCT02030028
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ACTHAR gel
Drug
Lead sponsor
Dana Ascherman
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 28, 2026, 12:17 AM EDT
Not listed Phase 2Phase 3 Interventional

ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study

NCT02155803
View directory record Official record
Conditions
Sarcoidosis, Hypercalcemia Due to Sarcoidosis
Interventions
ACTHAR Gel (adrenocorticotropic hormone)
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 28, 2026, 12:17 AM EDT
Completed Phase 4 Interventional Results available

Acthar Gel in Participants With Pulmonary Sarcoidosis

NCT03320070
View directory record Official record
Conditions
Sarcoidosis, Pulmonary
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Sep 28, 2026, 12:17 AM EDT
Not listed Phase 2Phase 3 Interventional

ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial

NCT02348905
View directory record Official record
Conditions
Sarcoidosis, Cutaneous Sarcoidosis
Interventions
ACTHAR Gel 40 units twice weekly, ACTHAR Gel 80 units twice weekly.
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Sep 28, 2026, 12:17 AM EDT
Completed Phase 2 Interventional Results available

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

NCT01906372
View directory record Official record
Conditions
Dermatomyositis, Polymyositis
Interventions
Adrenocorticotropic Hormone Gel
Drug
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Great Neck, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 28, 2026, 12:17 AM EDT
Not listed Phase 4 Interventional

Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis

NCT03066869
View directory record Official record
Conditions
Uveitis, Posterior, Vasculitis Retinal
Interventions
H.P. ACTHAR GEL
Drug
Lead sponsor
Ocular Immunology and Uveitis Foundation
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 28, 2026, 12:17 AM EDT
Not listed Phase 4 Interventional

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

NCT03082573
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
H.P. Acthar gel
Drug
Lead sponsor
Iraj Sabahi Research Inc.
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Pleasanton, California • Turlock, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 28, 2026, 12:17 AM EDT